Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | TPH1 | P17752 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.40 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.40 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.40 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.40 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.40 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.40 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.40 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12343971 | 0.90 | MCHR1 (0.44) | CNR1CNR2ROCK2MCHR1 | |
| SCHEMBL4950439 | 0.88 | CNR1 (0.54) | CNR1CNR2AKT1SCN9AADCY6 | |
| SCHEMBL2747835 | 0.88 | CNR1 (0.54) | CNR1CNR2AKT1SCN9AADCY6 | |
| SCHEMBL1246090 | 0.85 | BDKRB2 (0.38) | CNR1CNR2ROCK2MCHR1SCN9A | |
| SCHEMBL1244275 | 0.84 | MCHR1 (0.37) | CNR1CNR2ROCK2MCHR1SCN9A | |
| SCHEMBL4945104 | 0.81 | SCN9A (0.53) | CNR1CNR2SCN9AADCY6ADCY3 | |
| SCHEMBL4949380 | 0.81 | NPC1 (0.51) | ROCK2MCHR1 | |
| SCHEMBL5185512 | 0.81 | CNR2 (0.43) | CNR1CNR2ROCK2ADCY6ADCY3 | |
| SCHEMBL4949897 | 0.78 | TRPV1 (0.53) | CNR1CNR2MCHR1SCN9AADCY6 | |
| SCHEMBL4952022 | 0.78 | ROCK2 (0.44) | CNR1CNR2ROCK2MCHR1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | REMPEX PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | CNR1 4488/4885CNR2 4711/4885TPH1 3221/4885 |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | ABCB11, ABCB1, ABCC1 | CNR1 3772/4885CNR2 4069/4885TPH1 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.